87 related articles for article (PubMed ID: 15282438)
1. Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Chemotherapy; 2004 Jun; 50(3):107-12. PubMed ID: 15282438
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
4. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Rubinstein E
J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636
[No Abstract] [Full Text] [Related]
5. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Hayashi K; Kadowaki SE; Takei M; Fukuda H
Antimicrob Agents Chemother; 2006 Feb; 50(2):748-51. PubMed ID: 16436736
[TBL] [Abstract][Full Text] [Related]
6. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
[TBL] [Abstract][Full Text] [Related]
7. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
[TBL] [Abstract][Full Text] [Related]
8. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
[TBL] [Abstract][Full Text] [Related]
10. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae].
Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J
Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396
[TBL] [Abstract][Full Text] [Related]
11. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Tasso L; de Andrade C; Dalla Costa T
Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Azoulay-Dupuis E; Vallee E; Veber B; Bedos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2698-703. PubMed ID: 1336343
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.
Tillotson G; Zhao X; Drlica K
Lancet Infect Dis; 2001 Oct; 1(3):145-6. PubMed ID: 11871490
[No Abstract] [Full Text] [Related]
17. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
18. Activity of the new quinolone WCK 771 against pneumococci.
Appelbaum PC; Pankuch GA; Bozdogan B; Lin G; Jacobs MR; Patel MV; Gupte SV; Jafri MA; De Souza NJ; Khorakiwala HF
Clin Microbiol Infect; 2005 Jan; 11(1):9-14. PubMed ID: 15649298
[TBL] [Abstract][Full Text] [Related]
19. Activity of temafloxacin against respiratory pathogens.
Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
